Medication-prescribing patterns of primary care physicians in chronic kidney disease
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
We investigated the medication-prescribing patterns of primary care physicians in chronic kidney disease (CKD).
Subjects and methods
This cross-sectional study included 3,310 medical doctors who graduated from Jichi Medical University. The study instrument was a self-administered questionnaire to investigate their age group, specialty, workplace, existence of a dialysis center at workplace, and their prescription frequencies (high, moderate, low, very low) of the following agents—calcium (Ca) inhibitors, angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor antagonist (ARBs), statins, anti-platelet agents, erythropoietin (Epo), AST-120, vitamin D, and sodium hydrogen carbonate (NaHCO3).
From a total of 933 responses, 547 (61.0 %) medical doctors prescribed medication for CKD. The prescription frequencies of Ca inhibitors, ACEIs, and ARBs were high (>90 %, high + moderate), those of statins, anti-platelet agents, Epo, and AST-120 were moderate (90–50 %, high + moderate), and those of vitamin D and NaHCO3 were low (<50 %, high + moderate). The primary care physician’s specialty was significantly associated with their prescription frequency of Ca inhibitors (p < 0.01). Their workplace was significantly associated with their prescription frequency of ACEIs (p < 0.01), ARBs (p < 0.01), Epo (p < 0.01) and vitamin D (p < 0.01). The existence of a dialysis center at their workplace was significantly associated with their prescription frequency of Epo (p < 0.01), vitamin D (p < 0.01) and NaHCO3 (p < 0.01). Their age was not associated with their prescription frequency of any agents.
Antihypertensives were highly prescribed, and vitamin D and NaHCO3 were less prescribed by primary care physicians for CKD. There were certain associations between the prescribing patterns of primary care physicians for CKD and their specialty, workplace and the existence of a dialysis center at their workplace.
- K/DOQI clinical practice guidelines for chronic kidney disease. Evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1–266.
- Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, De Zeeuw D, Hostetter TH, Lameire N, Eknoyan G. Definition and classification of chronic kidney disease: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int. 2005;67:2089–100. CrossRef
- Kappel J, Calissi P. Nephrology: 3. Safe drug prescribing for patients with renal insufficiency. CMAJ. 2002;166:473–7.
- Gabardi S, Abramson S. Drug dosing in chronic kidney disease. Med Clin N Am. 2005;89:649–87. CrossRef
- Lopez-Novoa JM, Martinez-Salgado C, Rodriguez-Pena AB, Lopez-Hernandez FJ. Common pathophysiological mechanisms of chronic kidney disease: therapeutic perspectives. Pharmacol Ther. 2010;128:61–81. CrossRef
- Ritz E. Minor renal dysfunction: an emerging independent cardiovascular risk factor. Heart. 2003;89:963–4. CrossRef
- Al-Ramahi R. Medication prescribing patterns among chronic kidney disease patients in a hospital in Malaysia. Saudi J Kidney Dis Transpl. 2012;23:403–8.
- Roy P, Bouchard J, Amyot R, Madore F. Prescription patterns of pharmacological agents for left ventricular systolic dysfunction among hemodialysis patients. Am J Kidney Dis. 2006;48:645–51. CrossRef
- Vupputuri S, Batuman V, Muntner P, Bazzano LA, Lefante JJ, Whelton PK, He J. Effect of blood pressure on early decline in kidney function among hypertensive men. Hypertension. 2003;42:1144–9. CrossRef
- Perkovic V, Ninomiya T, Arima H, Gallagher M, Jardine M, Cass A, Neal B, Macmahon S, Chalmers J. Chronic kidney disease, cardiovascular events, and the effects of perindopril-based blood pressure lowering: data from the progress study. J Am Soc Nephrol. 2007;18:2766–72. CrossRef
- K/DOQI clinical practice guidelines on hypertension and antihypertensive. Agents in chronic kidney disease. Am J Kidney Dis. 2004;43:S1–290.
- McClellan W, Aronoff SL, Bolton WK, Hood S, Lorber DL, Tang KL, Tse TF, Wasserman B, Leiserowitz M. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin. 2004;20:1501–10. CrossRef
- Vlagopoulos PT, Tighiouart H, Weiner DE, Griffith J, Pettitt D, Salem DN, Levey AS, Sarnak MJ. Anemia as a risk factor for cardiovascular disease and all-cause mortality in diabetes: the impact of chronic kidney disease. J Am Soc Nephrol. 2005;16:3403–10. CrossRef
- Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, Ritz E. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353:238–48. CrossRef
- Shoji T, Masakane I, Watanabe Y, Iseki K, Tsubakihara Y. Elevated non-high-density lipoprotein cholesterol (non-HDL-C) predicts atherosclerotic cardiovascular events in hemodialysis patients. Clin J Am Soc Nephrol. 2011;6:1112–20. CrossRef
- Hatakeyama S, Yamamoto H, Okamoto A, Imanishi K, Tokui N, Okamoto T, Suzuki Y, Sugiyama N, Imai A, Kudo S, Yoneyama T, Hashimoto Y, Koie T, Kaminura N, Saitoh H, Funyu T, Ohyama C. Effect of an oral adsorbent, AST-120, on dialysis initiation and survival in patients with chronic kidney disease. Int J Nephrol. 2012;2012:376128.
- Ortega LM, Arora S. Metabolic acidosis and progression of chronic kidney disease: incidence, pathogenesis, and therapeutic options. Nefrologia. 2012;32:724–30.
- Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, Andress DL. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 2007;71:31–8. CrossRef
- Zehnder D, Landray MJ, Wheeler DC, Fraser W, Blackwell L, Nuttall S, Hughes SV, Townend J, Ferro C, Baigent C, Hewison M. Cross-sectional analysis of abnormalities of mineral homeostasis, vitamin D and parathyroid hormone in a cohort of pre-dialysis patients. The chronic renal impairment in Birmingham (CRIB) study. Nephron Clin Pract. 2007;107:c109–16. CrossRef
- McPhee SJ, Richard RJ, Solkowitz SN. Performance of cancer screening in a university general internal medicine practice: comparison with the 1980 American cancer society guidelines. J Gen Intern Med. 1986;1:275–81. CrossRef
- Evidence-based practice guideline for the treatment of CKD. Clin Exp Nephrol. 2009; 13:537–566.
- Medication-prescribing patterns of primary care physicians in chronic kidney disease
Clinical and Experimental Nephrology
Volume 18, Issue 5 , pp 690-696
- Cover Date
- Print ISSN
- Online ISSN
- Springer Japan
- Additional Links
- Primary care physician
- Chronic kidney disease
- Prescription pattern
- Industry Sectors
- Author Affiliations
- 1. Division of Nephrology, Department of Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi, 329-0498, Japan
- 2. Department of Medical Physiology, Meiji Pharmaceutical University, Tokyo, Japan